TECHNICAL ANALYSIS
ZBH
Zimmer Biomet
TECHNICAL RATING
TECHNICAL SCORE
88 / 100
Summary
Price sits above the 20-day (92.2), 50-day (95.0) and 200-day (91.08) moving averages, with the 50/200 having formed a Golden cross and the stock trading a few percent above each. Momentum is positive: MACD is above its signal line (MACD 1.0156 vs signal -0.0328) and RSI(14) at 64.2 is in the constructive band, so momentum is confirming the uptrend. The stock is inside the Bollinger bands rather than at an extreme, and recent volume is slightly above its 20-day average, which adds conviction to moves. Watch for a decisive drop back to the 20-day MA or a MACD cross below its signal; either would materially weaken this setup.
Price & Moving Averages
Volume
RSI (14)
MACD (12/26/9)
Formula & Methodology
Short-term trendPrice vs. 20-day moving average (weight 10%)
Intermediate trendPrice vs. 50-day moving average (weight 15%)
Long-term regimePrice vs. 200-day moving average (weight 25%)
Cross state50/200 Golden or Death cross (weight 10%)
Momentum + trendMACD 12/26/9 vs signal line (weight 15%)
Momentum bandsRSI (14) state (weight 10%)
VolatilityBollinger-band position (weight 5%)
ConfirmationVolume vs 20-day average (weight 10%)
Rating ruleFormula: the Technical Score is a weighted composite of eight inputs. Trend inputs — price vs. the 20-day (10%), 50-day (15%), and 200-day (25%) moving averages, and the 50/200 Golden or Death cross state (10%) — carry roughly 60% of the weight. Momentum inputs — MACD (12/26/9) vs. its signal line (15%) and RSI (14) state (10%) — carry 25%. Bollinger-band position (5%) and volume vs. the 20-day average (10%) round out the remainder. Each input contributes +1, 0, or -1, weights are re-normalized when a component is unavailable, and the weighted sum is thresholded at +/-0.45 to Bullish, Neutral, or Bearish.
Data Source
Market data sourced from Tiingo. End-of-day prices and volume power the charts and indicators (MA20/50/200, RSI, MACD, Bollinger Bands, Volume) on this page. This page is informational analysis, not investment advice. See Financial Disclaimer.